METHOD FOR TREATMENT OF CHILDREN IN EARLY POST-OPERATIVE PERIOD AFTER SURGERY AS TO CONGENITAL HYDRONEPHROSIS Russian patent published in 2006 - IPC A61K31/14 A61K31/4152 A61K31/135 A61K31/4425 A61P1/00 

FIELD: medicine, pediatrics, intensive therapy.

SUBSTANCE: method involves administration of ganglioblocker drug pentamine in the dose 0.6 mg/kg of child body mass immediately after finishing operation followed by carrying out the computer phonoenterography (CPEG). If the inhibition phase of peristalsis is 2 h by CPEG data then administration of pentamine is continued in the same dose in 6 h for 48 h. If the protective inhibition phase is less 2 h then the dose of the next administration of pentamine is increased to 0.7 mg/kg of patient body mass. If this schedule doesn't provide the required 2 h duration of phase of protective ganglionic inhibition then the dose of pentamine in the third administration is increased up to 0.8 mg/kg of child body mass. The selected dose of pentamine is administrated for the first and second day after operation, and then the pentamine dose is increased by 0.2 mg/kg of body mass and its administration is continued for the third day in 6 h after the post-operative period. Also, promedol is administrated additionally for the first 24 h after operation and in 1 h after administration of pentamine in the age dose as measured 0.1 ml of 1% solution per 1 year of child life. Then, in 3 h after administration of promedol the medicine analgin in combination with the medicine dimedrol is injected by intravenous route through subclavicular catheter in doses corresponding to age of child. For the next two days and in 1 h after administration of pentamine the drug analgin in combination with the drug dimedrol is administrated in place of promedol. Method provides the protective ganglionic inhibition that results to establishment of the sparing regimen required for healing urinary ways after operative surgery carrying out. Invention can be used in early post-operative period after operation as to congenital hydronephrosis.

EFFECT: improved method for treatment.

4 tbl, 2 ex